Severe acute respiratory syndrome coronavirus 2 genomic RNA (SARS-CoV-2 RNA)

Severe acute respiratory syndrome coronavirus 2 genomic RNA (SARS-CoV-2 RNA) is a large, positive-sense, single-stranded RNA molecule that serves as the genetic material for the virus responsible for COVID-19[1][3]. The genome is approximately 29.9 kilobases long and contains a 5′ cap and 3′ poly-A tail, functioning as both the template for viral protein translation and the substrate for replication and synthesis of subgenomic RNAs[2][1]. The genomic RNA contains conserved structural elements including the 5′ and 3′ untranslated regions (UTRs), the ribosomal frameshift element, and highly structured regions implicated in regulation of replication, transcription, and evasion of immune responses[1][3]. Due to its essential and central role in the viral life cycle, the RNA itself is a direct therapeutic target for nucleotide analogs (such as remdesivir and molnupiravir) that interact with the viral RNA-dependent RNA polymerase, as well as for RNA-targeted strategies including siRNAs and antisense oligonucleotides[1]. Structural understanding of SARS-CoV-2 RNA enables the rational design of these therapeutics[1][3]. Detection and quantification of SARS-CoV-2 RNA in patient samples is the diagnostic gold standard for COVID-19 and is used as a biomarker for viral load assessment and monitoring response to therapy.

Other names

SARS-CoV-2 genomeSARS-CoV-2 genomic RNASevere acute respiratory syndrome coronavirus 2 genomeSARS2 RNA

Inhibition of RNA-dependent RNA polymerase (e.g., remdesivir, molnupiravir); Induction of lethal mutagenesis via nucleotide analog incorporation (e.g., molnupiravir); Targeted cleavage or silencing of genomic RNA (siRNAs, ASOs)